Actively Recruiting
Genomic Determinants of Outcome in Cardiogenic Shock
Led by Barts & The London NHS Trust · Updated on 2025-11-18
300
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
Sponsors
B
Barts & The London NHS Trust
Lead Sponsor
U
University of Oxford
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.
CONDITIONS
Official Title
Genomic Determinants of Outcome in Cardiogenic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee
- Presentation within 24 hours of onset of acute coronary syndrome symptoms
- Cardiogenic shock secondary to acute coronary syndrome (Type 1 MI STEMI or N-STEMI) or myocarditis
- Planned or completed revascularisation of culprit coronary artery
- Cardiogenic shock defined by systolic blood pressure below 90 mmHg for at least 30 minutes
- Requirement for continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure above 90 mmHg
- Clinical signs of pulmonary congestion plus signs of impaired organ perfusion with at least one of the following: altered mental status, cold and clammy skin and limbs, urine output less than 30 ml per hour, or elevated arterial lactate level above 2.0 mmol per litre
You will not qualify if you...
- Not meeting all inclusion criteria
- Unwilling to provide informed consent
- Echocardiographic evidence of mechanical cause for cardiogenic shock (e.g., ventricular septal defect, left ventricular free wall rupture, ischaemic mitral regurgitation)
- Age less than 18 or 80 years and older
- Shock caused by other causes such as sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis
- Significant systemic illness
- Known dementia of any severity
- Comorbidity with life expectancy less than 12 months
- Out-of-hospital cardiac arrest with no return of spontaneous circulation, pH less than 7, or no bystander CPR within 10 minutes of collapse
- Arterial lactate level less than 2.0 mmol per litre
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barts Health NHS trust
London, United Kingdom
Actively Recruiting
Research Team
A
Alastair Proudfoot
CONTACT
M
Mervyn Andiapen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here